Komori
Earnings190AChordia Therapeutics Inc.Pharmaceuticals

Summary of Financial Results for the Third Quarter of the Fiscal Year Ending August 2026 [Japanese GAAP] (Non-consolidated)

For the cumulative third quarter of the fiscal year ending August 2026, there was no business revenue, but the operating loss narrowed from ¥1,420 million in the same period of the previous year to ¥1,070 million, mainly due to lower research and development expenses and other costs. There are no changes to the full-year earnings forecast or annual dividend forecast.

Worth reading
44Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
350
¥ million
Wording
Conditional
How definitive the wording is.

Results for this period

Third quarter1 September 2025 to 31 May 2026Non-consolidated (standalone)Japanese GAAP
Operating profit-1,070¥ million
Ordinary income-1,046¥ million
Net income attributable to owners of the parent-1,047¥ million

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.

Net income per share¥(14.45)
Financial position at period-end
Total assets2,585¥ million
of which net assets 2,333 ¥ millionEquity ratio 89.9%vs. prior year-end -0.9pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Cash and cash equivalents at end of period¥2,506 million
Outlook and shareholder returns
Full-year earnings forecast
Net SalesNot disclosed
Operating profit¥-2,008 million
Ordinary income¥-1,958 million
Net income¥-1,960 million
Annual Dividend Forecast¥0.00 → ¥0.00(0%)
Factors Behind Changes in Business Performance

No business revenue. Research and development expenses were ¥841 million, down 25.3% year on year, while other selling, general and administrative expenses were ¥229 million, down 22.3% year on year, resulting in narrower operating, ordinary and quarterly net losses than in the same period of the previous year.

Disclosure regarding the going concern assumption

Disclosure of matters concerning the going concern assumption is included. Although continuing operating losses and negative operating cash flow constitute events or conditions that raise substantial doubt about the going concern assumption, the company states that no material uncertainty regarding the going concern assumption has been identified.

Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNo
Issued Shares at Period-End77,258,400 shares
Treasury Shares at Period-End0 shares
Results for this period
ItemDetails
Fiscal Period ClassificationThird quarter
Accounting standardsJapanese GAAP
Consolidated / non-consolidatedNon-consolidated (standalone)
Period Covered1 September 2025 to 31 May 2026
Operating profit¥-1,070 million
Ordinary income¥-1,046 million
Profit attributable to owners of the parent¥-1,047 million
Net income per share¥(14.45)
Equity ratioEnd of the current fiscal period 89.9 / End of previous period 90.8
Total assets¥2,585 million
Net assets¥2,333 million
Cash and cash equivalents at end of period¥2,506 million
Full-year earnings forecastNet Sales Not disclosed / Operating profit ¥-2,008 million / Ordinary income ¥-1,958 million / Net income ¥-1,960 million
Annual Dividend Forecast¥0.00 → ¥0.00(0%)
Disclosure regarding the going concern assumptionDisclosure of matters concerning the going concern assumption is included. Although continuing operating losses and negative operating cash flow constitute events or conditions that raise substantial doubt about the going concern assumption, the company states that no material uncertainty regarding the going concern assumption has been identified.
Change in accounting policyChanges due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNo
Issued Shares at Period-End77,258,400 shares
Treasury Shares at Period-End0 shares
Factors Behind Changes in Business PerformanceNo business revenue. Research and development expenses were ¥841 million, down 25.3% year on year, while other selling, general and administrative expenses were ¥229 million, down 22.3% year on year, resulting in narrower operating, ordinary and quarterly net losses than in the same period of the previous year.
Items this document does not state (17)
Net SalesOperating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesRevision to Earnings ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlogDepreciation and amortizationImpairment lossBreakdown of extraordinary income (loss)Changes in the scope of consolidationMaterial subsequent events

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company explained that research and development expenses were ¥841 million, down 25.3% year on year, while other selling, general and administrative expenses were ¥229 million, down 22.3% year on year.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Summary of Financial Results for the Third Quarter of the Fiscal Year Ending August 2026 [Japanese GAAP] (Non-consolidated) | Chordia Therapeutics Inc. (190A) timely disclosure | Komori